How we evaluate every product
A $9 drugstore cleanser and a $300 serum go through the same evaluation. For each concern a product claims, three questions are answered from its ingredient list and a versioned evidence table, and a verdict in words is read off a published rule. No letter, no blended number. This page is the rulebook; the story of the whole town is told in Town Hall.
What goes in
- Regulators & guidelinesFDA monographs, approvals and treatment guidelines, each opened and dated.
- Published trials231 ingredient–concern rows, read paper by paper.
- The ingredient listWhat the label declares: which actives, at what strength, in what base.
The engine asks
- 1StandingDoes it contain an active with documented standing for this concern?
- 2FormIs that active present in a form and strength that can work?
- 3TolerabilityIs it likely to be tolerated by skin with this concern?
What comes out
- Strong choice
- Good choice
- Supporting role
- Promising · Unproven
- Not for this
- Avoid
One verdict per concern, with its receipt.
How a Verdict Is Decided
The answers are read against a rule tree, not weighted into a score. Every verdict on the site names the rule that produced it. A verdict is our assessment of how well a product’s ingredients fit a concern — never a claim that the product treats anything.
The scale
Every verdict word sits on one of six steps, and each step has one colour everywhere on the site. The colour is the step; the word is the reason. Learn the six once and every card reads the same way.
- RecommendedStrong choice · Full protection · Excellent at the jobA first-line or approved active in a form that works, with no trigger for the concern.
- GoodGood choice · Good choice (sensitivity) · Does the jobA supported active at a working level, or the right job done without a trigger.
- SupportingSupporting role · Basic protectionHelps the routine; does not treat the concern.
- Early evidencePromising · UnprovenA bet, not a recommendation; the dots say how much has been tested.
- Not for thisNot for this · Falls shortResearched and found wanting, or missing what the concern needs.
- AvoidAvoidThe formula carries a known trigger for this concern.
The words
A first-line active — approved, monograph-listed or named in current guidelines — at an effective strength, with no trigger for the concern.
A trial-supported active, or a reference standard by mechanism, at a working level; or a first-line active below its studied range.
Broad-spectrum SPF 30 or higher with an adequate UVA filter (and iron oxides where visible light matters).
Nothing here targets the concern directly, but the product’s job — barrier care, gentle cleansing, photoprotection — is the recognised companion to treating it. Rinse-off products carrying leave-on actives land here too.
Broad-spectrum SPF 15–29: meets the FDA bar for the early-skin-aging claim, below the SPF 30 dermatologists recommend daily.
The lead active has early or mechanistic evidence only, or is present below a working level. A reasonable bet, not a recommendation.
The lead active has at least one trial behind it for the concern but no guideline or regulatory standing yet, and is present at a working level. Short of a recommendation.
The actives have been researched for this concern and the evidence does not support the claim.
No evidence row yet for the actives on this concern — they are in the research queue, which is public.
A sunscreen missing what the concern needs: an adequate UVA filter, SPF 15, or iron oxides for visible light.
The formula carries a known trigger for the concern — fragrance for rosacea, comedogenic esters for acne, fungal triggers for fungal acne — which decides the verdict before any efficacy question.
Under each verdict sits a receipt: the document the standing rests on, the dose against the studied range, the date the row was checked, and the rule, with how many products share the reading. It opens into a full receipt page for the product. Beside it, four evidence dots say how much trial evidence stands behind the lead active for that concern — four need a guideline endorsement or a high-certainty replicated meta-analysis, three need at least one trial or a systematic review. The word answers “is it recognised for this?”; the dots answer “how much has it been tested?” They are two different questions, explained under Evidence.
Every Rule, With Its Reasoning rules 0.5.1 · evidence table ev-2026.10-r231
Rules are evaluated in order; the first that matches decides. Each is written out in words, with the condition the engine actually evaluates beneath it and the number of verdicts it decided on the current build. The register and its anchor set are editorial decisions, each with a written rationale; no advisory panel has reviewed them yet, and this page will say so until one has. Our Chief Medical Reviewer reads published pages afterwards as style and quality control — not as a gate — and nobody is named on a rule or a verdict.
Sensitivity (tolerability only) 3 rules
| Rule | Verdict | When, and why | Decided |
|---|---|---|---|
F1 | Avoid | The formula carries a known trigger for the concern.q3 = harshSensitivity has no efficacy claim; the verdict is tolerability. | 605 |
F2 | Good choice | The formula carries no trigger and no caution for the concern.q3 = gentleGentle = no weighted deduction fired and fit ≥ 90. | 1,955 |
F3 | Supporting role | Otherwise — when no earlier rule in this group matched.otherwiseStandard tolerability with a minor weighted leaf. | 184 |
Concerns 15 rules
| Rule | Verdict | When, and why | Decided |
|---|---|---|---|
R1 | Avoid | The formula carries a known trigger for the concern.q3 = harshSafety outranks praise (MASTER-PLAN §1.7). A condition-weighted trigger (multiplier ≥ 2 in condition-fit-matrix) decides the verdict before any efficacy question. | 1,307 |
R2r | Good choice | A first-line active (approved, monograph-listed or named in a current guideline) or a supported active (trial-backed, or a reference standard by mechanism); declared at a working strength, or a labelled active or at a plausible but undeclared level; in a rinse-off product the claim allows; not for a scalp concern.q1 = first-line | supported · q2 = adequate | plausible · rinse = true · scalp = falseRinse-off exceptions (BPO wash, salicylic acid cleanser) deliver a real but smaller effect than the leave-on form; they cap at 'good choice'. Medicated shampoos for scalp concerns are exempt — the shampoo is the treatment form. Editorial decision 2 Sep 2026, pending advisory review. | 413 |
R2 | Strong choice | A first-line active (approved, monograph-listed or named in a current guideline); declared at a working strength, or a labelled active.q1 = first-line · q2 = adequateA regulator- or guideline-recognised first-line active, declared at an effective strength, in a form the claim supports. | 905 |
R3 | Strong choice | A first-line active (approved, monograph-listed or named in a current guideline); at a plausible but undeclared level.q1 = first-line · q2 = plausibleUndeclared but plausibly dosed (top-third INCI position, or a potent sub-1% active) — the verdict stands, and the sentence says what disclosure would add. A declared figure below range would have been sub-threshold. | 570 |
R4 | Good choice | A first-line active (approved, monograph-listed or named in a current guideline); declared below the studied range.q1 = first-line · q2 = sub-thresholdRight molecule, weak dose: still a reasonable choice, not the strong one. | 84 |
R5 | Good choice | A supported active (trial-backed, or a reference standard by mechanism); declared at a working strength, or a labelled active or at a plausible but undeclared level.q1 = supported · q2 = adequate | plausibleTrial-supported or guideline-supported active, adequately or plausibly dosed. | 9,843 |
R6 | Supporting role | A first-line active (approved, monograph-listed or named in a current guideline) or a supported active (trial-backed, or a reference standard by mechanism) or an active with early or mechanistic evidence only or an active researched for the concern and found wanting or an active with no evidence row for the concern yet; in a rinse-off form the claim cannot use.q1 = first-line | supported | plausible | none | not-assessed · q2 = contact-limitedContact time cannot deliver a leave-on claim; the product is judged on its job (cleansing without aggravating). Explicit exceptions (BPO wash, SA cleanser, medicated shampoos) never reach this rule because their rows set rinse_off_ok. | 2,083 |
R7 | Supporting role | A supported active (trial-backed, or a reference standard by mechanism); declared below the studied range.q1 = supported · q2 = sub-thresholdA supported active under-dosed cannot be recommended for the concern; if the category has a supportive job it may still help alongside treatment. | 227 |
R8a | Supporting role | An active with early or mechanistic evidence only; declared at a working strength, or a labelled active or at a plausible but undeclared level; the product’s category job is a recognised companion to treating the concern.q1 = plausible · q2 = adequate | plausible · supportive = trueA plausible-tier active in a category with a supportive job: the sentence names the active instead of saying nothing targets the concern (the AmLactin / CeraVe SA case for keratosis pilaris, where no guideline and single trials leave the keratolytics at early evidence). | 1,509 |
R8 | Supporting role | An active with early or mechanistic evidence only or an active researched for the concern and found wanting or an active with no evidence row for the concern yet; the product’s category job is a recognised companion to treating the concern.q1 = plausible | none | not-assessed · supportive = trueThe category's job (barrier care, humectant hydration, gentle cleansing, photoprotection) is the documented supportive role for this concern. This is the honest verdict for a moisturizer on an acne page. | 3,793 |
R9p | Promising | An active with early or mechanistic evidence only; declared at a working strength, or a labelled active or at a plausible but undeclared level; the product’s category job is not a recognised companion to the concern; moderate or strong evidence dots on the carrier’s row.q1 = plausible · q2 = adequate | plausible · supportive = false · strength = moderate | strong0.5.0: 'Unproven' beside three filled dots read as one question answered twice with opposite words (7,018 rows). The chip measures standing, the dots measure trial volume; where the row carries at least one RCT or a tier-2 source (moderate dots) and the active is present at a working level, the honest word is Promising. Unproven is reserved for plausible-standing rows with limited or weak evidence, or an under-dosed form. Same rank as Unproven — a bet either way; the dots order them. | 4,872 |
R9 | Unproven | An active with early or mechanistic evidence only; the product’s category job is not a recognised companion to the concern.q1 = plausible · supportive = falsePlausible-tier actives alone do not earn a recommendation, and 'not for this' would overstate the case against them. 'Unproven' with the evidence dots lets the reader judge the bet (added 0.2.0 after the first shadow run put a 10% niacinamide serum at 'not for this' for hyperpigmentation). 0.5.0: the closing clause reads the other heroes — "nothing else here addresses it" only when every other active has a researched 'none' row; "not yet assessed" when that is the truth. Rows whose dots read moderate or better now reach R9p first. | 4,156 |
R10 | Not for this | An active researched for the concern and found wanting; the product’s category job is not a recognised companion to the concern.q1 = none · supportive = falseResearched and found wanting is a different sentence from unresearched (R11). | 489 |
R11 | Not yet assessed | An active with no evidence row for the concern yet; the product’s category job is not a recognised companion to the concern.q1 = not-assessed · supportive = falseNot assessed is a state, not a number (MASTER-PLAN §1.6). It can never outrank a researched active, and the backlog is published. | 9,844 |
R12 | Not for this | Neutralised by the rest of the formula.q2 = neutralisedThe 4.8.0 G5 self-neutralising rule, now a verdict rule. | 0 |
Sunscreens 5 rules
| Rule | Verdict | When, and why | Decided |
|---|---|---|---|
P1 | Full protection | An adequate UVA filter in the ingredient list; SPF 30 or higher; a concern not worsened by visible light.uva = true · spf_band = 30+ · iron_oxides_needed = falsePhotoprotection standing is regulatory (M020 / Annex VI filters; 21 CFR 201.327 attaches the early-skin-aging claim to tested broad-spectrum SPF 15+). SPF 30 is the AAD daily-use bar. | 2,280 |
P2 | Full protection | An adequate UVA filter in the ingredient list; SPF 30 or higher; a concern worsened by visible light; iron oxides present.uva = true · spf_band = 30+ · iron_oxides_needed = true · iron_oxides = trueMelasma needs visible-light attenuation; iron oxides are the documented route. | 56 |
P3 | Basic protection | An adequate UVA filter in the ingredient list; SPF 30 or higher; a concern worsened by visible light; no iron oxides.uva = true · spf_band = 30+ · iron_oxides_needed = true · iron_oxides = falseFull UV protection without the visible-light layer melasma needs. | 70 |
P4 | Basic protection | An adequate UVA filter in the ingredient list; SPF 15 to 29 or no SPF figure on record.uva = true · spf_band = 15-29 | unstatedSPF 15–29 broad-spectrum is protection, not the recommended level; 'falls short' would misstate a regulator-recognised product. | 107 |
P5 | Falls short | Otherwise — when no earlier rule in this group matched.otherwiseNo adequate UVA filter in the ingredient list is the one failure that makes a sunscreen fall short whatever its SPF. | 94 |
Category job 3 rules
| Rule | Verdict | When, and why | Decided |
|---|---|---|---|
J1 | Excellent at the job | The category-job reading is 85 or more over at least 4 measured features.job_score_min = 85 · job_measured_min = 4Category job score ≥ 85 over at least four measured features (0.5.1: three binary checks — UVA filter, photostability, tolerability — passed on 95 % of sunscreens and read 'Excellent' for a checklist; with fewer than four measurable features a category caps at Does the job). The concern verdicts carry the judgement; the job line states the function. | 374 |
J2 | Does the job | The category-job reading is 65 or more.job_score_min = 65Category job score over the measured features 65–85. | 5,096 |
J3 | Falls short | Otherwise — when no earlier rule in this group matched.otherwiseCategory job score below 65 over the features that can be measured from the label (5.1.0: unmeasured features no longer enter at a prior; when under half the spec's weight is measurable there is no job verdict). The sentence names the criterion missed, never 'its basics'. | 621 |
Triggers that make a formula an Avoid for a concern are listed per concern in the same register; cautions — a photosensitising active, a strong acid, a single declarable allergen — add a caution line to a verdict and never decide it. A Tier 1 or 2 seal from an expert body (the National Eczema Association, the Canadian Dermatology Association and their peers) outweighs a trigger for the concern the seal covers.
Where the Evidence Comes From
Underneath every verdict sits a versioned table of ingredient–claim pairs — currently 231 reviewed rows. A row is never “niacinamide is good”; it is “niacinamide for post-inflammatory hyperpigmentation”. Each records what the primary literature measured — design, population, dose, duration, endpoint — with its sources and review date. Its tier is computed from those findings, never typed in by judgement.
Three rules keep the table honest
A trial measuring post-inflammatory hyperpigmentation is evidence for PIH, never borrowed for melasma — which relapses and defeats treatments that clear PIH easily.
A positive result at 4% for 12 weeks is not evidence for a product containing 0.5%.
An unverifiable concentration is read as unknown and lowers stated confidence — never rounded up (crediting marketing) or down (punishing formulas that don’t disclose). An ingredient with no row for a concern is “not yet assessed”, not “weak”.
Two questions about every row
Standing asks whether the ingredient is recognised for the concern — and must rest on a document we opened and dated: a regulation, a guideline, a systematic review, never a person. Certainty asks how much dedicated evidence is behind it, derived by a fixed rule from trial count, replication, consistency and source quality. They are kept apart everywhere, because collapsing them would either overstate thin trials or hide real standing.
On every product page, the Key Ingredients table shows each hero’s standing and certainty for the concern it is read against, from the same table the verdicts use; the studies are one tap away. Every citation on the site is checked by machine against the source database before it publishes — the title, journal and year at the link must match the reference — because a plausible link to the wrong study is worse than no link.
Four Things You Can Check Without Asking
A method is only as good as what a sceptic can open. These four pages are generated from the same files the engine runs on, every build.
Every row: ingredient, concern, standing and its document, the counted trials, the studied dose, every source with the date it was opened.
The research queueEvery ingredient and concern in the catalogue with no row yet, by the products it would decide. What we have not assessed.
The anchorsThe product–concern pairs whose verdict the engine must produce, each with its reason, checked against the current build.
The changelogEvery engine and rules version, what moved and why. Verdicts change for stated reasons, never quietly.
And for any product, its receipt page — linked under every verdict — holds the rule, the row, the sources and the dates behind each verdict on that product.
None of it is frozen. As formulas change and research is published, verdicts are re-derived: every new row in the evidence table updates every verdict that depends on it, across the catalogue at once.
What 62 Dermatologists Agree On
In 2025, the Journal of the American Academy of Dermatology published a Delphi consensus: 62 board-certified cosmetic dermatologists from 43 academic centres, asked in 2 rounds which ingredients they would recommend for seven everyday concerns. It is the clearest picture yet of what practising experts reach for. We use it as a check on our own evidence table: where the panel and the table agree, that is reassuring; where they differ, we look again.
- ingredients found in the literature
- kept by a first panel of 17 experts
- rated by 62 dermatologists, after 6 were added
- reached consensus for at least one concern
What counts as consensus
At least 70% of panelists rated it 7 to 9 on a 9-point scale, no more than 15% rated it 1 to 3, and the consensus meeting accepted it.
Each panelist rated how likely they were to recommend an ingredient for a concern, from 1 (strongly discourage) to 9 (strongly recommend).
Agreement, ingredient by concern
Share of the 62 panelists who would recommend each ingredient. Only pairs that reached consensus are shown; a blank cell means the panel did not agree, not that it disagreed. Tap or hover a cell for the evidence level and our own standing.
| Ingredient | Fine lines | Acne | Redness | Dark spots | Large pores | Dry skin | Oily skin |
|---|---|---|---|---|---|---|---|
| Retinoids | 96.8% 1b | 96.8% 1b | No consensus | 96.8% 1b | 93.6% 2b | No consensus | 93.6% 2b |
| Mineral sunscreen | 96.8% 1b | No consensus | 95.2% 2b | No consensus | No consensus | No consensus | No consensus |
| Benzoyl peroxide | No consensus | 95.2% 1b | No consensus | No consensus | No consensus | No consensus | 80.7% opinion |
| Salicylic acid | No consensus | 93.6% 2b | No consensus | No consensus | No consensus | No consensus | 79% 2b |
| Glycolic acid | No consensus | 79% 2b | No consensus | 91.9% 2b | No consensus | No consensus | No consensus |
| Azelaic acid | No consensus | 87.1% 2b | No consensus | 88.7% 2a | No consensus | No consensus | No consensus |
| Vitamin C | 88.7% 1b | No consensus | No consensus | 87.1% 1b | No consensus | No consensus | No consensus |
| Niacinamide | No consensus | No consensus | 72.6% 2b | 79% 2b | No consensus | No consensus | No consensus |
| HydroquinoneRx | No consensus | No consensus | No consensus | 98.4% 1b | No consensus | No consensus | No consensus |
| Kojic acid | No consensus | No consensus | No consensus | 93.6% 2b | No consensus | No consensus | No consensus |
| ClindamycinRx | No consensus | 90.3% 1b | No consensus | No consensus | No consensus | No consensus | No consensus |
| Tranexamic acid | No consensus | No consensus | No consensus | 87.1% 1b | No consensus | No consensus | No consensus |
| Petrolatum | No consensus | No consensus | No consensus | No consensus | No consensus | 85.5% 2b | No consensus |
| Chemical sunscreen | 82.3% 1b | No consensus | No consensus | No consensus | No consensus | No consensus | No consensus |
| Sulfacetamide-sulfurRx | No consensus | No consensus | 82.3% 2b | No consensus | No consensus | No consensus | No consensus |
| Ceramides | No consensus | No consensus | No consensus | No consensus | No consensus | 82.1% 1b | No consensus |
| MetronidazoleRx | No consensus | No consensus | 79% 2b | No consensus | No consensus | No consensus | No consensus |
| Ammonium lactate | No consensus | No consensus | No consensus | No consensus | No consensus | 79% 1b | No consensus |
| Hyaluronic acid | No consensus | No consensus | No consensus | No consensus | No consensus | 79% 1b | No consensus |
| Urea | No consensus | No consensus | No consensus | No consensus | No consensus | 79% 2b | No consensus |
| Green-tinted products | No consensus | No consensus | 77.4% opinion | No consensus | No consensus | No consensus | No consensus |
| BrimonidineRx | No consensus | No consensus | 75.8% 1b | No consensus | No consensus | No consensus | No consensus |
| IvermectinRx | No consensus | No consensus | 72.6% 2b | No consensus | No consensus | No consensus | No consensus |
How strong is the evidence behind it?
For every consensus pair, the authors looked up the best published study and graded it on the Oxford scale.
- Level 1bA randomised trial15 of 34 (44.1%)
- Level 2aA review of cohort studies1 of 34 (2.9%)
- Level 2bA cohort study or smaller trial16 of 34 (47.1%)
- Level 5Expert opinion only2 of 34 (5.9%)
Two recommendations rest on expert opinion alone: benzoyl peroxide for oily skin, and green-tinted products to hide redness. The panel's own limitation, in its words: the results are based on expert opinion.
Why a check, and not an input
A Delphi panel tells you what experienced clinicians recommend, which is valuable and hard to get any other way. It is still opinion: the lowest step on the evidence ladder, shaped in places by cost and insurance (the authors say so), and it rates ingredient classes such as “retinoids” rather than the molecule in a given bottle.
So it does not set a verdict. Our standing comes from guidelines, regulators and trials, ingredient by ingredient. The panel is how we test that table from the outside, the same way we test the engine against anchor products.
How our table lines up
Each of the panel's 34 recommendations, matched to the strongest row in our evidence table for the same ingredient and concern. Read live from the table on every build.
- Azelaic acid · acne
- Azelaic acid · dark spots
- Benzoyl peroxide · acne
- Ceramides · dry skin
- Chemical sunscreen · fine lines
- Hyaluronic acid · dry skin
- Hydroquinone · dark spots
- Ivermectin · redness
- Kojic acid · dark spots
- Metronidazole · redness
- Mineral sunscreen · fine lines
- Petrolatum · dry skin
- Retinoids · fine lines
- Retinoids · acne
- Retinoids · dark spots
- Salicylic acid · acne
- Tranexamic acid · dark spots
- Glycolic acid · acneThin
- Glycolic acid · dark spotsThin
- Mineral sunscreen · rednessThin
- Niacinamide · rednessThin
- Niacinamide · dark spotsEmerging
- Retinoids · large poresEmerging
- Retinoids · oily skinThin
- Salicylic acid · oily skinThin
- Sulfacetamide-sulfur · rednessThin
- Vitamin C · fine linesThin
- Vitamin C · dark spotsThin
- Ammonium lactate · dry skin
- Benzoyl peroxide · oily skin
- Brimonidine · redness
- Clindamycin · acne
- Green-tinted products · redness
- Urea · dry skin
Where we are more cautious than the panel, that is a statement about written evidence, not a claim that the ingredient doesn't work. Sixty-two dermatologists recommending something is real information, and those pairs are first in line in the research queue.
Source: Alvarez GV, Kang BY, Richmond AM, et al.; Alam M. Skincare ingredients recommended by cosmetic dermatologists: A Delphi consensus study. J Am Acad Dermatol 2025;93:1509-1525.
Reading Reviews Instead of Counting Stars
A 4.7-star average tells you a product pleased people; it can’t tell you it failed everyone with rosacea. So we read review text, collected from retailer and platform APIs and passed through a fixed extraction model — measured against human coding at κ = 0.851, a level of agreement generally considered strong. It reads what people with a specific concern reported, and flags undisclosed promotional reviews — in our pilot, on some products a third to a half of reviews turned out to be seeded placements, invisible in the star average everyone shops by. Where reviews haven’t been collected for a product, its verdict rows say so in as many words, and the verdict stands on formulation and evidence rather than on a guess.
Readers can also answer for themselves. Every product page carries a short poll: have you used it, and how did it go for your concern. Answers are shown to everyone only once 25 people have given one, and they sit beside the verdict, never inside it. The live polls in the Town Square, on a dozen well-known products, show their tally straight away. A poll records what people report; it is a useful signal, not clinical evidence.
What Nothing Can Outweigh
Some findings disqualify a product however well its ingredients read. A gate can only be entered through its published criteria — never by editorial judgement — and every gate has exit criteria, a review schedule, a disputed state for findings under formal challenge, and a written appeal path. Two gates read from the ingredient list and fire today (category integrity, self-neutralising formula). The other four need a public record — a recall notice, a regulator’s finding, documented review manipulation, a settled expert consensus — and their register is public and currently empty: no product sits behind any of them. The page says so rather than letting an empty list read as a clean bill.
An active recall or a verified contamination finding.
Marketing that asserts clinical results the evidence contradicts.
Documented seeding or manipulation of user reviews.
A “sunscreen” without adequate UVA filtration — derived from its own ingredient list.
A formulation that inactivates its own hero ingredient.
A settled expert consensus that the product does nothing.
Hype-Aware, Never Cynical
Not every product earns the attention it gets. We apply friendly skepticism where it’s warranted — always assessing the formula on its merits, never punching down, and never mocking the people who love a product.
The name on the label got you here — we focus on what’s inside the bottle, give credit where it’s earned, and flag when a price reflects fame rather than ingredients.
Virality is not an ingredient. When the main credential is “sold out three times,” we look for the substance behind the aesthetic — and say so clearly when it’s there.
A $90 moisturizer should earn its price in the formula, not the packaging. If the ingredient list reads like a $20 product in a heavier jar, we say so — diplomatically, but clearly.
Fear-based claims like “free from toxins” get a factual answer. We help readers tell meaningful from marketing, without mocking anyone who cares.
A pharmaceutical, regulatory or big-industry claim meets the same evidence bar as an indie or influencer one. When independent critics have been right — inflated SPF labels caught by outside labs, recalls forced by independent testing — we say so first, plainly. Where we disagree with a concern, we concede the true part and then show the evidence; where solid trials exist, they win.
The Numbers You Don’t See
Beneath the verdicts, a deterministic engine still scores each formula across six factors — formula quality, safety and tolerability, real-world results, usability, value, and brand trust. No number is shown on a product page or a card: a verdict says what a number cannot, and a number invites a ranking the evidence does not support. The engine’s job is quieter — it supplies the tolerability answer inside every verdict, the category “job” reading, and the safety gates above, and it unfolds into a citable audit trail. Every fact has exactly one owner (fragrance in safety, texture in usability, price in value), and value is never derived from popularity.
What’s in Every Review
Beside the verdict, every product gets an 800–1,500 word editorial review — written by someone who understands formulation science, opening with an angle of its own rather than a template.
The evidence behind the key actives, focused on the combination and delivery system in that formula. If a study can’t be confirmed, we describe the evidence base instead of citing it.
Clinical context from publicly available dermatologist guidance, in the third person — never impersonating a specific doctor.
A frank read on whether the price matches the formula — including when you’re paying for packaging.
How and when to apply it, what to expect at first, a sample routine, who should buy and who should skip, and honest pros and cons.
Ready to Find Better Products?
Set up your skin profile and browse products that actually fit your skin.
Start With My Skin